[go: up one dir, main page]

WO2010040083A3 - Prédicteurs de chimiorésistance par expression génique - Google Patents

Prédicteurs de chimiorésistance par expression génique Download PDF

Info

Publication number
WO2010040083A3
WO2010040083A3 PCT/US2009/059423 US2009059423W WO2010040083A3 WO 2010040083 A3 WO2010040083 A3 WO 2010040083A3 US 2009059423 W US2009059423 W US 2009059423W WO 2010040083 A3 WO2010040083 A3 WO 2010040083A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
chemotherapeutic agent
methods
chemoresistance
gene expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/059423
Other languages
English (en)
Other versions
WO2010040083A2 (fr
Inventor
Jeffrey E. Green
Hark K. Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of WO2010040083A2 publication Critical patent/WO2010040083A2/fr
Publication of WO2010040083A3 publication Critical patent/WO2010040083A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G01N33/5758—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des signatures génétiques décrivant des profils génétiques. Les signatures génétiques peuvent prédire si un sujet atteint d'un cancer, tel qu'un cancer de l'estomac, sera chimiorésistant ou chimiosensible à une chimiothérapie à base de cisplatine et de fluorouracile. L'invention décrit ainsi des méthodes permettant de déterminer si un sujet atteint d'un cancer sera sensible à un traitement avec un agent chimiothérapeutique. L'invention décrit des méthodes permettant d'augmenter la sensibilité à l'agent chimiothérapeutique si EGFR, FGFR-2 et MYC sont augmentés, cette augmentation indiquant que le cancer présente une sensibilité diminuée à un agent chimiothérapeutique. L'invention décrit également des méthodes permettant d'augmenter la sensibilité à l'agent chimiothérapeutique si un ou plusieurs marqueurs de cellules souches embryonnaires ou une ou plusieurs cibles MYC sont augmentés, cette augmentation indiquant que le cancer présente une sensibilité diminuée à un agent chimiothérapeutique.
PCT/US2009/059423 2008-10-03 2009-10-02 Prédicteurs de chimiorésistance par expression génique Ceased WO2010040083A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19512308P 2008-10-03 2008-10-03
US61/195,123 2008-10-03
US17839209P 2009-05-14 2009-05-14
US61/178,392 2009-05-14

Publications (2)

Publication Number Publication Date
WO2010040083A2 WO2010040083A2 (fr) 2010-04-08
WO2010040083A3 true WO2010040083A3 (fr) 2010-06-24

Family

ID=41506489

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/059423 Ceased WO2010040083A2 (fr) 2008-10-03 2009-10-02 Prédicteurs de chimiorésistance par expression génique

Country Status (1)

Country Link
WO (1) WO2010040083A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481688B2 (en) 2010-05-11 2013-07-09 Aveo Pharmaceuticals, Inc. Anti-FGFR2 antibodies
CN107254546B (zh) * 2017-08-16 2020-11-03 复旦大学附属华山医院 一种与乳腺癌新辅助化疗疗效相关的snp标志物及其应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201390370A1 (ru) 2010-09-15 2013-07-30 Олмак Дайэгностикс Лимитед Молекулярно-диагностический тест для определения онкологического заболевания
WO2013071502A1 (fr) * 2011-11-17 2013-05-23 Genedia Biotech Co Ltd Gène mir-193a-3p et gènes associés prédisant la tumorigenèse et les résultats d'une chimiothérapie
AU2013295815A1 (en) * 2012-07-24 2015-02-05 Cedars-Sinai Medical Center A novel method to detect resistance to chemotherapy in patients with lung cancer
EP2695950A1 (fr) * 2012-08-10 2014-02-12 Blackfield AG Marqueurs pour la réactivité à un inhibiteur du récepteur du facteur de croissance des fibroblastes
GB201316027D0 (en) * 2013-09-09 2013-10-23 Almac Diagnostics Ltd Molecular diagnostic test for oesophageal cancer
WO2018177325A1 (fr) * 2017-03-29 2018-10-04 Crown Bioscience Inc. (Taicang) Système et méthode de détermination de la sensibilité au cétuximab dans le cancer gastrique
CN111057762B (zh) * 2019-11-28 2022-11-08 中国人民解放军陆军军医大学第一附属医院 检测基因在制备检测食管鳞癌对顺铂敏感性的制剂中的用途
CN118308488A (zh) * 2024-05-08 2024-07-09 河南省胸科医院 Oct4作为人食管鳞状细胞癌放疗敏感性预测的标志物及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060037088A1 (en) * 2004-08-13 2006-02-16 Shulin Li Gene expression levels as predictors of chemoradiation response of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060037088A1 (en) * 2004-08-13 2006-02-16 Shulin Li Gene expression levels as predictors of chemoradiation response of cancer

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
"[HG-U133A] Affymetrix Human Genome U133A Array", GEO,, 11 March 2002 (2002-03-11), XP002527544 *
H. K. KIM, I. J. CHOI, C. G. KIM, A. OSHIMA AND J. E. GREEN: "Gene expression signatures to predict the response of gastric cancer to cisplatin and fluorouracil", JOURNAL OF CLINICAL ONCOLOGY, vol. 27, no. 15s, 20 May 2009 (2009-05-20), pages 4628, XP002565666, Retrieved from the Internet <URL:http://meeting.ascopubs.org/cgi/content/abstract/27/15S/4628> [retrieved on 20100127] *
HAMILTON ET AL: "A Review of the Genomics of Gastric Cancer", CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, AMERICAN GASTROENTEROLOGICAL ASSOCIATION, US, vol. 4, no. 4, 1 April 2006 (2006-04-01), pages 416 - 425, XP005367985, ISSN: 1542-3565 *
HSU DAVID S ET AL: "Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 25, no. 28, 1 October 2007 (2007-10-01), pages 4350 - 4357, XP002513951, ISSN: 0732-183X *
KIHARA C ET AL: "Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD., US, vol. 61, no. 17, 1 September 2001 (2001-09-01), pages 6474 - 6479, XP002960719, ISSN: 0008-5472 *
KNECHT RAINALD ET AL: "EGFR antibody-supplemented TPF-chemotherapy. Preclinical investigations to a novel approach for head and neck cancer induction treatment", ANTICANCER RESEARCH, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, vol. 23, no. 6C, 1 November 2003 (2003-11-01), pages 4789 - 4795, XP009128280, ISSN: 0250-7005 *
METZGER R ET AL: "ERCC1 MRNA LEVELS COMPLEMENT THYMIDYLATE SYNTHASE MRNA LEVELS IN PREDICTING RESPONSE AND SURVIVAL FOR GASTRIC CANCER PATIENTS RECEIVING COMBINATION CISPLATIN AND FLUOROURACIL CHEMOTHERAPY", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 16, no. 1, 1 January 1998 (1998-01-01), pages 309 - 316, XP001118953, ISSN: 0732-183X *
NAPIERALSKI RUDOLF ET AL: "Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 11, no. 8, 15 April 2005 (2005-04-15), pages 3025 - 3031, XP002551877, ISSN: 1078-0432 *
NISHIMURA T ET AL: "Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer.", CLINICAL CANCAR RESEARCH, vol. 2, 1 November 1996 (1996-11-01), pages 1859 - 1865, XP002565665 *
ROTOLO SABRINA ET AL: "Silencing of Keratinocyte Growth Factor Receptor Restores 5-Fluorouracil and Tamoxifen Efficacy on Responsive Cancer Cells", PLOS ONE, vol. 3, no. 6, June 2008 (2008-06-01), XP002565668, ISSN: 1932-6203 *
STEWART ET AL: "Mechanisms of resistance to cisplatin and carboplatin", CRITICAL REVIEWS IN ONCOLOGY / HEMATOLOGY, ELSEVIER SCIENCE IRELAND LTD., LIMERICK, IE, vol. 63, no. 1, 1 July 2007 (2007-07-01), pages 12 - 31, XP025320373, ISSN: 1040-8428, [retrieved on 20070528] *
WANG W., ET AL: "Establishment and biological characteristics of a multi-drug resistant cell line A549/Gem", CHIN J LUNG CANCER, vol. 11, no. 1, February 2008 (2008-02-01), pages 55 - 61, XP002565667, Retrieved from the Internet <URL:http://www.lungca.org/index.php?journal=01&page=article&op=viewFile&path%5B%5D=16&path%5B%5D=20> [retrieved on 20100128], DOI: 10.3779/j.issn.1009-3419.2008.01.014 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481688B2 (en) 2010-05-11 2013-07-09 Aveo Pharmaceuticals, Inc. Anti-FGFR2 antibodies
CN107254546B (zh) * 2017-08-16 2020-11-03 复旦大学附属华山医院 一种与乳腺癌新辅助化疗疗效相关的snp标志物及其应用

Also Published As

Publication number Publication date
WO2010040083A2 (fr) 2010-04-08

Similar Documents

Publication Publication Date Title
WO2010040083A3 (fr) Prédicteurs de chimiorésistance par expression génique
WO2010030365A3 (fr) Identification de tumeurs de la tyroïde
WO2008094678A3 (fr) Signature pronostique moléculaire pour prédire des métastases distantes chez les femmes atteintes d&#39;un cancer du sein, et ses utilisations
WO2009037572A3 (fr) Combinaisons de bio-marqueurs du cancer colorectal
EP2524059A4 (fr) Détection d&#39;affections gastro-intestinales
WO2012021887A3 (fr) Biomarqueurs pour la détection précoce du cancer du sein
WO2011082198A3 (fr) Biomarqueurs du cancer permettant de prédire la récurrence et le potentiel métastasique
GB2507458A (en) Automated detection of flaws and incompatibility problems in information flow downgraders
EP2016423A4 (fr) Methodes de detection de carence en fer
WO2012074904A3 (fr) Procédés et systèmes pour l&#39;évaluation de la sensibilité ou de la résistance des échantillons tumoraux vis-à-vis d&#39;agents chimio-thérapeutiques
WO2012068400A3 (fr) Micro-arn utilisés comme biomarqueurs pour faire la distinction entre des néoplasmes thyroïdiens bénins et malins
WO2008153987A3 (fr) Procédés pour la détermination d&#39;un sous-type de carcinome hépatocellulaire et la détection de cellules souches du cancer du foie
WO2010125566A3 (fr) Marqueurs pour la détection d&#39;un cancer
WO2010099342A3 (fr) Procédés de détection du cancer du poumon
WO2009034481A3 (fr) Biomarqueur de méthylation pour une détection précoce du cancer gastrique
WO2009038754A3 (fr) Signatures de l&#39;expression génique dans des échantillons de cellules tumorales enrichis
MY170983A (en) Biomarker assays for detecting or measuring inhibition of tor kinase activity
WO2007082144A3 (fr) Methode permettant de detecter un cancer a l&#39;aide de b7-h1 et de survivine
WO2009094647A3 (fr) Biomarqueurs p53
WO2008097908A3 (fr) Procédés de diagnostic et de pronostic d&#39;un cancer du poumon
WO2011085163A3 (fr) Marqueurs de protéine pour détection du cancer du poumon et leurs procédés d&#39;utilisation
WO2008023840A3 (fr) Marqueurs pronostiques et cibles thérapeutiques s&#39;appliquant au cancer du poumon
WO2014008312A3 (fr) Amorces, dosages et méthodes de détection d&#39;un sous-type d&#39;e. coli
WO2012027631A3 (fr) Méthodes pour la détection d&#39;anticorps anti-he4 et méthodes de diagnostic et/ou de pronostic d&#39;états associés à des cellules exprimant he4
WO2010034794A3 (fr) Procédés et kits de diagnostic et de stadification du cancer colorectal

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09793289

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09793289

Country of ref document: EP

Kind code of ref document: A2